Elan

Elan Dividend per Share

The Dividend per Share of Elan (6099.T) as of Oct 29, 2026 is 15.00 JPY. In the previous year, Dividend per Share was 13.00 JPY — a change of 15.38% (higher).

Dividend per Share

15.00JPY

YoY

15.38%

Last updated:

Dividend per Share of Elan is 2025 15.00 JPY. Dividend per Share of Elan was 2024 13.00 JPY. It decreases by 15.38% higher compared to the previous year.

At today's price the dividend yield works out to roughly 2.10%. The payout ratio is around 33% of earnings. The dividend has grown at 42.2% per year over the past 11 years.

The Elan Dividend per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Dividend per Share
Date
Dividend per Share
Jan 1, 2021
9.00 JPY
Jan 1, 2022
11.00 JPY
Jan 1, 2023
13.00 JPY
Jan 1, 2024
13.00 JPY
Jan 1, 2025
15.00 JPY
Jan 1, 2026 (e)
28.00 JPY
Jan 1, 2027 (e)
28.00 JPY
Jan 1, 2028 (e)
28.00 JPY
The Elan Dividend per Share history
YEARDividend per ShareYoY
est28.00JPY0.00%
est28.00JPY0.00%
est28.00JPY+86.67%
15.00JPY+15.38%
13.00JPY0.00%
13.00JPY+18.18%
11.00JPY+22.22%
9.00JPY+28.57%
7.00JPY+55.56%
4.50JPY+28.57%
3.50JPY+75.00%
2.00JPY+33.33%
1.50JPY+300.00%
0.38JPY+20.00%
0.31JPY—
0.00JPY—
0.00JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

Dividend per Share of Elan is 15.00 JPY in 2025.

Dividend per Share of Elan changed from 13.00 JPY to 15.00 JPY, representing a 15.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Dividend per Share Elan since 2006 – with annual values, charts, and detailed analysis.

Dividend per share is the total dividend payment divided by shares outstanding. It shows how much cash each share receives in dividends.

Dividend per Share's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend per Share's Elan historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Dividend — Elan

All Key Metrics — Elan